The Story of OpenBiome

The human gut is teeming with trillions of bacteria and other microbes. Understanding this mysterious part of our body is key to unlocking the future of medicine.

At OpenBiome, we’ve seen the life-saving power of bacteria firsthand. Here’s a look at our journey so far to advance microbiome science.

  • A Life-Changing Investigational Fecal Transplant

    January 1, 2011

    A close friend of ours contracts a life-threatening C. difficile infection after a routine surgery. We watch him struggle through several rounds of failed antibiotic treatment for 18 months. After receiving an investigational fecal microbiota transplantation (FMT), his health rebounds within a few days.

    Learn more about Investigational FMT
  • OpenBiome is Founded

    January 15, 2013

    OpenBiome started as an initiative run out of an MIT-based laboratory. In 2013, we were officially founded as an independent nonprofit devoted to expanding access to investigational FMT and catalyzing microbiome research.

    Meet Our Team
  • The First OpenBiome Treatment

    November 14, 2013

    OpenBiome ships its first investigational FMT preparation to a hospital in Oakland, California. The patient—a 91 year-old woman who has experienced three recurrences of C. difficile—recovers from the infection.

    See Our Impact
  • Reaching New Milestones

    February 1, 2016

    OpenBiome manufactures and ships its 10,000th investigational FMT preparation.

  • Expanding Our Mission Globally

    March 1, 2017

    OpenBiome launches the Global Health Microbiome Initiative. Our first study explores whether investigational FMT can help treat severe acute malnutrition in children. It's the first investigational FMT clinical trial on the African continent.

    How We Work With Researchers
  • Another Milestone Met

    September 1, 2021

    OpenBiome manufactures and ships its 60,000th investigational FMT preparation.

  • An icon of a clinician with a stool sample

    Working with the University of Minnesota to Treat Patients with Recurrent C. difficile Infections

    January 20, 2022

    OpenBiome enters a collaboration with the University of Minnesota’s Microbiota Therapeutics Program to ensure that patients with recurrent C. difficile infections have access to investigational fecal microbiota transplantation (FMT). Through this collaboration, OpenBiome will distribute preparations of intestinal microbiota manufactured under Good Manufacturing Practice by the University of Minnesota under the guidance of gastroenterologist Alexander Khoruts, MD and microbiologist Michael Sadowsky, PhD.

    Read more
  • OpenBiome Ships 70,000th Investigational FMT

    February 13, 2024

    OpenBiome passes the milestone of shipping its 70,000th investigational Fecal Microbiota Transplantation (FMT) preparation for the treatment of recurrent Cloistridiodes difficile infection, a life-threatening disease, and to advance clinical research on the microbiome.

    Read More

Help us build a world where the full potential of the microbiome radically improves health for all

Scroll To Top